COMMISSION REGULATION (EU) …/…

of XXX

setting out scientific criteria for the determination of endocrine disrupting properties
and amending Annex II to Regulation (EC) 1107/2009

(Text with EEA relevance)
THE EUROPEAN COMMISSION,

Having regard to the Treaty on the Functioning of the European Union,


Whereas:

(1) Scientific criteria for the determination of endocrine disrupting properties of active substances, safeners and synergists, should be developed taking into account the objectives of Regulation (EC) No 1107/2009, which are to ensure a high level of protection of both human and animal health and the environment, in particular ensuring that substances or products placed on the market have no harmful effect on human or animal health or unacceptable effects on the environment, and to improve the functioning of the internal market while improving agricultural production.

(2) In 2002, the World Health Organisation (WHO) through its International Programme for Chemical Safety proposed a definition for endocrine disruptors and in 2009 a definition of adverse effects. Those definitions have by now reached the widest consensus among scientists. The European Food Safety Authority (‘the Authority’) endorsed those definitions in its Scientific Opinion on endocrine disruptors adopted on 28 February 2013 (hereinafter "the Scientific Opinion of the Authority"). It is also the view of the Scientific Committee on consumer Safety. It is therefore appropriate to

base the criteria for the determination of endocrine disrupting properties on those WHO definitions.

(3) In order to implement those criteria, weight of evidence should be applied considering in particular the approach provided for in Regulation (EC) No 1272/2008 of the European Parliament and Council\(^6\) on the weight of evidence. Previous experience with the Guidance document on standardised test guidelines for evaluating chemicals for endocrine disruption of OECD\(^7\) should also be considered. In addition, the implementation of the criteria should be based on all relevant scientific evidence, including studies submitted in accordance with the current regulatory data requirements of Regulation (EC) No 1107/2009. These studies are mostly based on internationally agreed study protocols.

(4) As the specific scientific criteria laid down by this Regulation reflect the current scientific and technical knowledge and are to be applied instead of the criteria currently set out in point 3.6.5 of Annex II to Regulation (EC) No 1107/2009, they should be provided for in that Annex.

(5) In order to take into account the current scientific and technical knowledge, specific scientific criteria should also be specified in order to identify active substances, safeners or synergists having endocrine disrupting properties that may cause adverse effects on non-target organisms. Therefore point 3.8.2 of Annex II to Regulation (EC) No 1107/2009 should be amended to introduce these specific criteria.

(6) The first paragraph of point 3.6.5 and point 3.8.2 of Annex II to Regulation (EC) No 1107/2009 currently provide that an active substance, safener or synergist meeting the criteria to be considered as having endocrine disrupting properties that may cause adverse effects on humans or non-target organisms respectively\(^6\) may be approved in the case the exposure of humans or non-target organisms, respectively, to the substances, safeners or synergist is negligible under realistic proposed conditions of use.

(7) However the Scientific Opinion of the Authority states that endocrine disruptors may be assessed like most other substances of concern for human health and the environment, that is to say may also be subject to risk assessment, instead of hazard assessment. The Authority specifies that the approach concerning substances with endocrine disrupting properties is to be based on a level of concern and that whether or not this level of concern is reached, can only be determined by risk assessment. The Scientific Committee on Consumer Safety (SCCS) supports the use of risk assessment to assess endocrine disruptors in its Memorandum\(^8\) issued in 2014.

(8) Union provisions on endocrine disrupting properties of chemical substances which entered into force later than Regulation (EC) No 1107/2009 should be also taken into consideration, in particular as regards similar criteria set out in Regulation (EU) No 528/2012 of the European Parliament and of the Council.


\(^{7}\) OECD Series on Testing and Assessment No. 150.

It is also necessary to ensure that the level of residues of active substances, to be approved or renewed, having endocrine disrupting properties do not, taking account of the most recent relevant opinion of the Authority, present an unacceptable risk to humans or to animals respectively, and are kept as low as possible in accordance with good agricultural practice for each pesticide with a view to protecting vulnerable groups such as children and the unborn, in accordance with Regulation (EC) No 396/2005 of the European Parliament and of the Council.

In order to reflect current scientific and technical knowledge in accordance with Article 78(1)(a) of Regulation (EC) No 1107/2009, an active substance, safener or synergist should only be approved if it is not considered to have endocrine disrupting properties that may cause adverse effect in humans or on non-target organisms, respectively, unless the risk to humans or to non-target organisms, respectively, from exposure to that active substance, safener or synergist in a plant protection product under realistic proposed conditions of use is negligible. Points 3.6.5 and 3.8.2 of Annex II to Regulation (EC) No 1107/2009 should therefore be amended accordingly.

The criteria for the determination of endocrine disrupting properties reflect the current state of scientific and technical knowledge and allow identifying active substances having endocrine disrupting properties more accurately. The new criteria should therefore apply as soon as possible, except where the relevant Committee has voted on the draft Regulation presented to it without that Regulation having been adopted by the Commission by [Date of EIF]. The Commission will consider the implications for each procedure pending under Regulation (EC) No 1107/2009 and, where necessary, take appropriate measures with due respect for the rights of the applicants. This may include a request for additional information from the applicant and/or for additional scientific input from the Rapporteur Member State and the Authority.

The measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on Plants, Animals, Food and Feed,

HAS ADOPTED THIS REGULATION:

Article 1

Annex II to Regulation (EC) No 1107/2009 is amended in accordance with the Annex to this Regulation.

Article 2

Point 3.6.5 and point 3.8.2 of Annex II to Regulation (EC) No 1107/2009, as amended by the present Regulation, shall apply as of [date of EIF of the Regulation], except for procedures where the Committee has voted on the draft Regulation presented to it without that draft Regulation having been adopted by [date of EIF this Regulation].

Article 3

This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.
This Regulation shall be binding in its entirety and directly applicable in all Member States.
Done at Brussels,

For the Commission
The President
Jean-Claude JUNCKER
ANNEX 1

DRAFT

ANNEX

to the

COMMISSION REGULATION (EU) .../...

setting out scientific criteria for the determination of endocrine disrupting properties
and amending Annex II to Regulation (EC) 1107/2009
ANNEX

 Annex II to Regulation (EC) No 1107/2009 is amended as follows:

(1) Point 3.6.5. is replaced by the following:

"3.6.5. Endocrine disrupting properties

3.6.5.1. An active substance, safener or synergist shall only be approved if, on the basis of the assessment of Community or internationally agreed test guidelines or other available data and information, including a review of the scientific literature, reviewed by the Authority, it is not considered to have endocrine disrupting properties that may cause adverse effect in humans, unless the exposure of humans to that active substance, safener or synergist in a plant protection product, under realistic proposed conditions of use, is negligible, that is, the product is used in closed systems or in other conditions excluding contact with humans and where residues of the active substance, safener or synergist concerned on food and feed do not exceed the default value set in accordance with point (b) of Article 18(1) of Regulation (EC) No 396/2005.

By 14 December 2013, the Commission shall present to the Standing Committee on the Food Chain and Animal Health a draft of the measures concerning specific scientific criteria for the determination of endocrine disrupting properties to be adopted in accordance with the regulatory procedure with scrutiny referred to in Article 79(4).

Pending the adoption of these criteria, substances that are or have to be classified, in accordance with the provisions of Regulation (EC) No 1272/2008, as carcinogenic category 2 and toxic for reproduction category 2, shall be considered to have endocrine disrupting properties.

In addition, substances such as those that are or have to be classified, in accordance with the provisions of Regulation (EC) No 1272/2008, as toxic for reproduction category 2 and which have toxic effects on the endocrine organs, may be considered to have such endocrine disrupting properties.

3.6.5.2. From [date of EIF], the following shall apply instead of the first, the third and the fourth paragraph of point 3.6.5.1.

3.6.5.2.1. An active substance, safener or synergist shall only be approved if, on the basis of the assessment of the available evidence carried out in accordance with the data requirements for the active substances, safeners or synergists and other available data and information, it is not considered, in accordance with the criteria specified in point 3.6.5.2.2, to have endocrine disrupting properties that may cause adverse effect in humans, unless the risk to humans from exposure to that active substance, safener or synergist in a plant protection product, under realistic worst case proposed conditions of use, is negligible, in particular where the product is used in closed systems or in other conditions which aim at excluding contact with humans, and where maximum residue levels of the active substance, safener or synergist concerned in or on food and feed can, taking account of the latest opinion of the Authority with respect to that active substance, synergist, safener, be set in accordance with Regulation (EC) No 396/2005, which ensure a high level of consumer protection.
3.6.5.2.2. An active substance, safener or synergist shall be considered as having endocrine disrupting properties that may cause adverse effect in humans if, based on points (1) to (4) of point 3.6.5.2.3., it is a substance that meets all of the following criteria, unless there is information demonstrating that the adverse effects identified are not relevant to humans:

(1) it shows an adverse effect in an intact organism or its progeny, which is a change in the morphology, physiology, growth, development, reproduction, or, life span of an organism, system, or (sub)population that results in an impairment of functional capacity, an impairment of the capacity to compensate for additional stress, or an increase in susceptibility to other influences;

(2) it has an endocrine mode of action, i.e. it alters the function(s) of the endocrine system;

(3) the adverse effect is a consequence of the endocrine mode of action.

3.6.5.2.3. The identification of an active substance, safener or synergist as having endocrine disrupting properties that may cause adverse effect in humans in accordance with point 3.6.5.2.2. shall be based on all of the following:

(1) all available relevant scientific data:

   (a) scientific data generated in accordance with internationally agreed study protocols (in vivo studies or adequately validated alternative test systems predictive of adverse effects in humans or animals; as well as in vivo or in vitro studies informing about endocrine modes of action). In particular, those internationally agreed study protocols listed in the Commission Communications in the framework of setting out the data requirements for active substances and plant protection products, in accordance with Regulation (EC) No 1107/2009 shall be considered.

   (b) other relevant scientific data selected applying a systematic review methodology, in particular following guidance listed in the Commission Communications in the framework of setting out the data requirements for active substances and plant protection products, in accordance with Regulation (EC) No 1107/2009.

(2) an assessment of the available relevant scientific data based on a weight of evidence approach in order to establish whether the criteria set out in point 3.6.5.2.2 are fulfilled.

(3) in applying the weight of evidence determination, the assessment of quality, reliability, reproducibility and consistency of the scientific evidence shall, in particular, consider all of the following factors:

   (a) both positive and negative results.

   (b) the relevance of the study designs, for the assessment of adverse effects and of the endocrine mode of action.

   (c) the biological plausibility of the link between the adverse effects and the endocrine mode of action.

   (d) the quality and consistency of the data, considering the pattern and coherence of the results within and between studies of a similar design and across different species.
(e) the route of exposure, toxicokinetic and metabolism studies.

(f) the concept of the limit dose, and international guidelines on maximum recommended doses and for assessing confounding effects of excessive toxicity.

(4) adverse effects that are non-specific secondary consequences of other toxic effects shall not be considered for the identification of the substance as endocrine disruptor."

(2) Point 3.8.2. is replaced by the following:

"3.8.2 Endocrine disrupting properties

3.8.2.1. An active substance, safener or synergist shall only be approved if, on the basis of the assessment of Community or internationally agreed test guidelines, it is not considered to have endocrine disrupting properties that may cause adverse effects on non-target organisms unless the exposure of non-target organisms to that active substance in a plant protection product under realistic proposed conditions of use is negligible.

3.8.2.2. From [date of EIF], the following shall apply instead point 3.8.2.1.

3.8.2.2.1 An active substance, safener or synergist shall only be approved if it is not considered, in accordance with the criteria specified in point 3.8.2.2.2, to have endocrine disrupting properties that may cause adverse effects on non-target organisms, unless the risk to the non-target organisms from exposure to that active substance, safener or synergist in a plant protection product, under realistic worst case proposed conditions of use, is negligible.

3.8.2.2.2 An active substance, safener or synergist shall be considered as having endocrine disrupting properties that may cause adverse effects on non-target organisms if, based on points (1) to (4) of point 3.8.2.2.3, it is a substance that meets all of the following criteria, unless there is information demonstrating that the adverse effects identified are not relevant at the (sub)population level for non-target organisms:

(1) it shows an adverse effect in non-target organisms, which is a change in the morphology, physiology, growth, development, reproduction, or, life span of an organism, system, or (sub)population that results in an impairment of functional capacity, an impairment of the capacity to compensate for additional stress, or an increase in susceptibility to other influences, considered relevant at the (sub)population level;

(2) it has an endocrine mode of action, i.e. it alters the function(s) of the endocrine system;

(3) the adverse effect is a consequence of the endocrine mode of action

3.8.2.2.3 The identification of an active substance, safener or synergist as having endocrine disrupting properties that may cause adverse effects on non-target organisms in accordance with point 3.8.2.2.2 shall be based on all of the following:

(1) all available relevant scientific data:

(a) scientific data generated in accordance with internationally agreed study protocols (in vivo studies or adequately validated alternative test systems
predictive of adverse effects in humans or animals; as well as in vivo or in vitro studies informing about endocrine modes of action). In particular, those internationally agreed study protocols listed in the Commission Communications in the framework of setting out the data requirements for active substances and plant protection products, in accordance with Regulation (EC) No 1107/2009 shall be considered.

(b) other relevant scientific data selected applying a systematic review methodology, in particular following guidance listed in the Commission Communications in the framework of setting out the data requirements for active substances and plant protection products, in accordance with Regulation (EC) No 1107/2009.

(2) an assessment of the available relevant scientific data based on a weight of evidence approach in order to establish whether the criteria set out in point 3.8.2.2.2 are fulfilled.

(3) in applying the weight of evidence determination, the assessment of quality, reliability, reproducibility and consistency of the scientific evidence shall consider all of the following factors:

(a) both positive and negative results, discriminating between taxonomic groups (e.g. mammals, birds, fish) where relevant.

(b) the relevance of the study design for the assessment of the adverse effects and its relevance at the (sub)population level, and for the assessment of the endocrine mode of action.

(c) the adverse effects on reproduction and growth/development, as these are the effects most likely to impact on (sub)populations. Adequate, reliable and representative field or monitoring data and/or results from population models shall be considered where available.

(d) the biological plausibility of the link between the adverse effects and the endocrine mode of action.

(e) the quality and consistency of the data, considering the pattern and coherence of the results within and between studies of a similar design and across different taxonomic groups.

(f) the concept of the limit dose and international guidelines on maximum recommended doses and for assessing confounding effects of excessive toxicity.

(4) Adverse effects that are non-specific secondary consequences of other toxic effects shall not be considered for the identification of the substance as endocrine disruptor with respect to non-target organisms."